Coagulation factor VIII

**Indication**: Haemophilia A  
**ICD11 code**: 3B10.0

**Medicine type**: Biological agent

**List type**: Complementary

**Additional notes**: All human plasma-derived medicines should comply with the WHO requirements.

**Formulations**: Parenteral > General injections > IV: 500 IU in vial powder for injection

**EML status history**
- First added in 1979 (TRS 641)
- Changed in 1984 (TRS 722)
- Changed in 1989 (TRS 796)
- Changed in 2007 (TRS 950)
- Changed in 2013 (TRS 985)
- Changed in 2021 (TRS 1035)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**: Therapeutic alternatives to be reviewed (2023)

**Therapeutic alternatives limitations for EMLc**: Therapeutic alternatives to be reviewed (2023)

**Patent information**: Read more about patents.

**Wikipedia**: Coagulation factor VIII

**DrugBank**: Coagulation factor viii (Antihemophilic factor human)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the therapeutic alternatives for coagulation factors be reviewed.